ATE298246T1 - Aktiviertes protein c zur behandlung von pankreatitis - Google Patents
Aktiviertes protein c zur behandlung von pankreatitisInfo
- Publication number
- ATE298246T1 ATE298246T1 AT01918217T AT01918217T ATE298246T1 AT E298246 T1 ATE298246 T1 AT E298246T1 AT 01918217 T AT01918217 T AT 01918217T AT 01918217 T AT01918217 T AT 01918217T AT E298246 T1 ATE298246 T1 AT E298246T1
- Authority
- AT
- Austria
- Prior art keywords
- activated protein
- pancreatitis
- treatment
- disease
- pathological condition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19275500P | 2000-03-28 | 2000-03-28 | |
PCT/US2001/005823 WO2001072328A2 (en) | 2000-03-28 | 2001-03-21 | Methods of treating diseases with activated protein c |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE298246T1 true ATE298246T1 (de) | 2005-07-15 |
Family
ID=22710924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01918217T ATE298246T1 (de) | 2000-03-28 | 2001-03-21 | Aktiviertes protein c zur behandlung von pankreatitis |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1267915B1 (de) |
JP (1) | JP2003528153A (de) |
AT (1) | ATE298246T1 (de) |
AU (1) | AU2001245319A1 (de) |
CA (1) | CA2404231A1 (de) |
DE (1) | DE60111620T2 (de) |
ES (1) | ES2242740T3 (de) |
PT (1) | PT1267915E (de) |
WO (1) | WO2001072328A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE286122T1 (de) | 2000-02-02 | 2005-01-15 | Lilly Co Eli | Protein c derivate |
WO2001059084A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
ES2384099T3 (es) * | 2001-06-13 | 2012-06-29 | The University Of Sydney | Proteína C para cicatrización de heridas |
DE10158561A1 (de) * | 2001-11-29 | 2003-06-12 | Bayer Ag | Neue Verwendung von Cyclopentabenzofuranen |
EP1567199B1 (de) * | 2002-12-05 | 2014-07-23 | Zz Biotech L.L.C. | Neuroprotektive wirkung von aktiviertem protein c ist unabhängig von seiner gerinnungshemmenden wirkung |
JP4986618B2 (ja) * | 2003-07-08 | 2012-07-25 | ザ スクリプス リサーチ インスティチュート | 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインc変異体 |
US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
RU2595857C2 (ru) * | 2012-05-31 | 2016-08-27 | Кинки Юниверсити | Средство для профилактического и/или терапевтического лечения периферической нейропатической боли, вызываемой противораковым средством |
CA2877745C (en) | 2012-07-04 | 2021-11-30 | The University Of Sydney | Treatment of inflammatory skin disorders |
CA2946028C (en) | 2014-04-16 | 2022-10-11 | Zz Biotech Llc | Treatment of abnormal cutaneous scarring |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
JP4256497B2 (ja) * | 1998-08-06 | 2009-04-22 | 旭化成ファーマ株式会社 | 血管炎治療剤 |
JP2000219633A (ja) * | 1999-01-29 | 2000-08-08 | Chemo Sero Therapeut Res Inst | 虚血性腎障害の予防・治療剤 |
-
2001
- 2001-03-21 CA CA002404231A patent/CA2404231A1/en not_active Abandoned
- 2001-03-21 WO PCT/US2001/005823 patent/WO2001072328A2/en active IP Right Grant
- 2001-03-21 JP JP2001570289A patent/JP2003528153A/ja active Pending
- 2001-03-21 ES ES01918217T patent/ES2242740T3/es not_active Expired - Lifetime
- 2001-03-21 DE DE60111620T patent/DE60111620T2/de not_active Expired - Lifetime
- 2001-03-21 EP EP01918217A patent/EP1267915B1/de not_active Expired - Lifetime
- 2001-03-21 AT AT01918217T patent/ATE298246T1/de not_active IP Right Cessation
- 2001-03-21 PT PT01918217T patent/PT1267915E/pt unknown
- 2001-03-21 AU AU2001245319A patent/AU2001245319A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2404231A1 (en) | 2001-10-04 |
AU2001245319A1 (en) | 2001-10-08 |
DE60111620T2 (de) | 2006-05-18 |
EP1267915B1 (de) | 2005-06-22 |
DE60111620D1 (de) | 2005-07-28 |
WO2001072328A2 (en) | 2001-10-04 |
ES2242740T3 (es) | 2005-11-16 |
PT1267915E (pt) | 2005-09-30 |
JP2003528153A (ja) | 2003-09-24 |
WO2001072328A3 (en) | 2002-02-14 |
EP1267915A2 (de) | 2003-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
ATE262336T1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
DE60328476D1 (de) | Medizinisches ballonsystem zur behandlung von adipositas | |
ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний | |
DE60130365D1 (de) | Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen. | |
ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
ATE343387T1 (de) | S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen. | |
DE60017174D1 (de) | Rivastigmine zur behandlung von augenerkrankungen | |
ATE516038T1 (de) | Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen | |
DE69905489D1 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
DE60302495D1 (de) | Landwirtschaftliche Maschine zur Behandlung von Erntegut | |
DE60318274D1 (de) | Autonome landwirtschaftliche Maschine zur Behandlung von Erntegut | |
DE60219495D1 (de) | Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten | |
DE69813354T2 (de) | Mittel zur Behandlung von Herzkrankheiten | |
DE10193322D2 (de) | Verwendung von Protonenpumpen-Hemmern zur Behandlung von Erkrankungen des Bewegungsapparates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1267915 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |